Pharmacological approaches to pulmonary fibrosis following COVID-19
Background: In the past few years, COVID-19 became the leading cause of morbidity and mortality worldwide. Although the World Health Organization has declared an end to COVID-19 as a public health emergency, it can be expected, that the emerging new cases at the top of previous ones will result in a...
Saved in:
Main Authors: | Stefan Lassan (Author), Tomas Tesar (Author), Jana Tisonova (Author), Monika Lassanova (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2023-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Analysis of spontaneous reports of suspected adverse reactions after vaccination against COVID-19 in Slovakia
by: Monika Lassanova, et al.
Published: (2023) -
Pharmacological Interactions of Nintedanib and Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis in Times of COVID-19 Pandemic
by: José M. Serra López-Matencio, et al.
Published: (2021) -
The Management of Pulmonary Fibrosis in COVID-19
by: Cleopas Martin Rumende, et al.
Published: (2021) -
Research on the mechanism of berberine in the treatment of COVID-19 pneumonia pulmonary fibrosis using network pharmacology and molecular docking
by: Junfeng Cao, et al.
Published: (2022) -
Exploring the Mechanism Whereby Sinensetin Delays the Progression of Pulmonary Fibrosis Based on Network Pharmacology and Pulmonary Fibrosis Models
by: Yong Xu, et al.
Published: (2021)